Nutriband Showcases AVERSA™ Abuse-Deterrent Technology at Emerging Growth Conference

Nutriband Inc. (NASDAQ: NTRB) CEO Serguei Melnik showcased the company's AVERSA™ abuse-deterrent transdermal technology at the August 2025 Emerging Growth Conference, highlighting its potential to address the ongoing opioid crisis. The proprietary technology integrates aversive agents to prevent misuse, abuse, and accidental exposure of drugs with high abuse potential, particularly opioids. This innovation aims to transform traditional transdermal patches into safer tools for patients requiring powerful pain relief while reducing risks that have contributed to a national epidemic.

The AVERSA™ platform represents a significant advancement in drug delivery systems, with AVERSA™ fentanyl projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million. The technology's development comes at a critical time when the opioid crisis continues to underscore the urgent need for safer, more secure drug delivery methods. Nutriband's approach differs from many biotechnology companies as it sustains itself through multiple revenue-generating subsidiaries rather than relying solely on investor capital.

Founded in 2016, Nutriband completed its IPO in 2021 and has positioned itself as a company with a viable solution to pharmaceutical safety concerns. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. The presentation detailed how AVERSA™ technology works to deter abuse through integrated aversive agents, making it difficult to extract and misuse the active pharmaceutical ingredients from transdermal patches.

This technology development aligns with growing regulatory and public health demands for abuse-deterrent formulations in pain management medications. The potential market impact of AVERSA™ technology extends beyond financial projections, representing a meaningful contribution to public health efforts to combat prescription drug abuse. As the company continues to develop and commercialize this technology, it addresses both medical needs and societal concerns surrounding opioid medications.